SLS Sellas Life Sciences Group Inc
Company Analysis
Latest News
🟢 Sellas Life Sciences is trading 4.08% up today as REGAL trial nears final-analysis procedures
Sellas Life Sciences is trading 4.08% up now at $12.25 as investors continued digesting its August 11 earnings release and clinical update. - Management...
🟢 Sellas Life Sciences is trading 8.15% up today after Q2 report and REGAL trial progress
On August 12, 2026, Sellas Life Sciences is trading at $11.93, +8.15% following its August 11 second-quarter report, which matched the $0.05 loss-per-share...
SELLAS Life Sciences met second quarter 2026 EPS estimates while advancing pivotal Phase 3 REGAL trial
SELLAS Life Sciences reported a net loss for the second quarter of 2026 that met analyst expectations, despite a significant increase in operating expenses...
🔴 Sellas Life Sciences is trading 4.08% down today ahead of August 11 earnings report
Sellas Life Sciences is trading now 4.08% down at $11.52 as investors await its August 11, 2026, earnings report. - No new company-specific announcement was...
Sellas Life Sciences Group Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Sellas Life Sciences is expected to report a Q2 2026 net loss of $0.05 per share on zero revenue, with the stock currently trading at $12.01 against an average...
Sellas Life Sciences Surges 10.8% on Trial Hopes and Fresh Institutional Buying — But Can a Single Data Readout Justify the Bet?
Shares of Sellas Life Sciences (SLS) jumped 10.8% to $11.09 on August 7, rebounding sharply from a late-July pullback, as investors piled in ahead of what may...
🟢 Sellas Life Sciences is trading 4.2% up today as REGAL trial optimism and institutional interest fuel rebound
Sellas Life Sciences is trading at $11.69 (up 4.2%) as its recent rebound extends following a strong move in the prior session. • Investors remain focused on...
🟢 Sellas Life Sciences is trading 10.8% up today on REGAL trial optimism and institutional interest
Sellas Life Sciences is trading 10.8% up today at $11.09, extending its recent rebound after last week’s pullback. • Bullish sentiment is being driven by...
🟢 Sellas Life Sciences is trading 5.9% up today on REGAL trial optimism and institutional interest
Sellas Life Sciences is trading at $10.60 (+5.9%) as the stock continues its recent upward trajectory fueled by positive clinical and funding narratives. •...
🟢 Sellas Life Sciences is trading 5.6% up today on strong cash runway and upcoming REGAL trial trigger
Sellas Life Sciences is trading 5.6% up today at $10.66 as investors refocus on the company's $138.3 million cash position and upcoming clinical milestones. •...
🔴 Sellas Life Sciences is trading 11.68% down today following earnings and 3D Medicines arbitration loss
Sellas Life Sciences is trading 11.68% down at $9.57 following its July 27 earnings update and a significant legal setback involving a lost binding arbitration...
🔴 Sellas Life Sciences is trading 8% down today after losing arbitration case against 3D Medicines
Sellas Life Sciences is trading 8% down at $9.76 today after disclosing it lost a binding arbitration case against 3D Medicines alongside its July 2026...
SELLAS reports $138.3 million in cash for its second quarter 2026 and loses its arbitration case against 3D Medicines.
SELLAS Life Sciences Group provided a preliminary update on its cash position as of June 30, 2026, and announced the result of its arbitration proceeding...
Sellas Life Sciences Drops 10% on REGAL Trial Anxiety — But Is the Delay Actually Good News in Disguise?
Shares of Sellas Life Sciences (SLS) slid 10.1% to $10.18 on Monday as investors bailed out amid growing unease that top-line data from the company's...
🔴 Sellas Life Sciences is trading 10.1% down today on Phase 3 REGAL AML delay concerns
Sellas Life Sciences is trading 10.1% down at $10.18 as investors react to perceived delays in the Phase 3 REGAL AML trial data release. • Traders are focused...
🔴 Sellas Life Sciences is trading 5.48% down today on Phase 3 REGAL AML trial delay concerns
Sellas Life Sciences is trading at $10.70 (-5.48%) as shares extend a pullback driven by investor uncertainty regarding clinical trial timelines. • Market...
🔴 Sellas Life Sciences is trading 4.4% down today on reports of potential Phase 3 trial data delays
Sellas Life Sciences is trading 4.4% down at $11.80 following online commentary suggesting a potential delay in the release of its Phase 3 REGAL trial data for...
Sellas Shares Sink, Martin Shkreli Predicts AML Trial Delay
Sellas Life Sciences shares fell after former hedge fund manager Martin Shkreli questioned the timing of its Phase 3 REGAL trial. Shkreli suggested on social...
🟢 Sellas Life Sciences is trading 5.1% up
Sellas Life Sciences is trading at $12.70, up 5.1% from a comparison close of $12.08 during regular trading. This is a price-action follow-up, so a separate...
Sellas Investor Slashes Stake by 33%, Ahead of Pivotal Cancer Data
Fulcrum Wealth Advisors reduced its stake in Sellas Life Sciences by 33%, according to reports published late Tuesday and early Wednesday. The wealth advisor...